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Purpose: FERM domain containing 7 (FRMD7) is a member of the four-point-one, ezrin, radixin, moesin (FERM) family
of proteins, and has been reported to cause X-linked idiopathic congenital nystagmus (ICN), a disease which affects ocular
motor control. There have been over 30 mutations reported for FRMD7, however, their role in the pathogenesis of ICN
remains unclear. The purpose of this study is to perform the expression distributes of protein FRMD7 from human fetal
brain during development and to understand the relationship with cytoskeletal protein F-actin between wild-type and
mutation-type FRMD7.
Methods: Expression of protein FRMD7 from developing human fetal brain was tested by immunohistochemistry.
Enhanced green fluorescent protein (EGFP)-tagged recombinant plasmids DNA encoding the normal or mutant FRMD7
were used to transiently transfect the mouse neuroblastoma cells (Neuro-2a) and human embryonic kidney 293 cells
(HEK293T). Further, confocal microscopic analysis was used to determine the subcellular localization of the fusion
proteins. To visualize F-actin, fixed HEK293T cells were stained with rhodamine-phalloidin.
Results: We show that expression of FRMD7 was mainly detected in the brainstem (a region associated with ocular motor
control), while limited level was observed in the cortex. The COOH-terminus of FRMD7 was found to play a key role in
the subcellular localization of FRMD7 in mouse neuroblastoma cells (Neuro-2a) and human embryonic kidney 293 cells
(HEK293T). While no differences in the co-localization of F-actin between the wild-type and missense mutation-type (c.
781C>G and c.886G>C) proteins was observed, an additional mutant, c.1003C>T, which results in a COOH-terminally
truncated protein, exhibited a nuclear localization pattern which did not co-localize with the cytoplasmic distribution of
F-actin.
Conclusions: The results of the present study indicate that FRMD7 may play an important role in the brainstem in the
early stages of development of the human fetal brain, and provides clues for the mechanism of mutation FRMD7, which
may be involved in influencing F-actin dynamics.
Idiopathic congenital nystagmus (ICN) is an oculomotor
disorder that results from defects in the regions of the brain
responsible  for  ocular  motor  control.  This  disorder  is
characterized  by  involuntary  bilateral  ocular  pendular
oscillations that occur within six months of birth, and can be
sustained  over  a  lifetime.  As  a  result,  patients  with  ICN
experience a significant decrease in their quality of life [1].
Currently, the incidence of ICN is estimated to be 24 cases/
10,000, and there is no effective treatment available [2].
Mutations in the FRMD7 gene are a main cause of ICN,
and more than 30 different mutations have been reported
[3-9]. The FRMD7 gene consists of 12 exons, encodes 714
amino  acids,  and  shares  a  four-point-one,  ezrin,  radixin,
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moesin (FERM) domain at its NH2-terminus with band 4.1,
ezrin, moesin, radixin, talin, filopodin, and merlin. As a result,
FRMD7  has  been  shown  to  regulate  the  adhesion  and
morphogenesis  of  cells  by  modulating  changes  in  the
cytoskeleton [10,11].
Eye movement is controlled by some brain regions, such
as  the  cortex,  brainstem,  and  cerebellum  [12,13].  In  situ
hybridization  studies  have  shown  that  FRMD7  mRNA  is
mainly expressed in the cortex plate at the early fetal cortex
in  humans,  and  at  the  brain  cortex  in  mice  [14,15].  For
example, an evaluation of five developmental stages of the
human embryonic brain (including Carnegie stages 15, 16, 19,
22, and 23), as well as two developmental stages of the human
fetal  brain  (9-  and  14-weeks  post-conception  [wpc]),
identified  strong  hybridization  signals  associated  with  the
cortex [14]. There are other regions of the brain that also affect
eyeball movement, however, expression of FRMD7 has not
been characterized in those areas.
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591When FRMD7 was knocked down in Neuro-2a cells,
altered development of neurites was observed during retinoic
acid-induced differentiation [14]. A notable increase in the
dynamics of F-actin and F-actin/G-actin were also observed
when FRMD7 was down-regulated in Neuro-2a cells [14].
Therefore,  it  has  been  postulated  that  FRMD7  regulates
neuronal development by influencing the dynamics of F-actin.
However, the precise function of FRMD7, and in particular
its involvement in ICN pathogenesis, remain incompletely
characterized. Therefore, in the present study, the expression
and  localization  of  FRMD7  was  investigated  in  the
developing human fetal brain. These studies included both
wild-type FRMD7, and three mutated versions of FRMD7,
which elucidated a role for F-actin in the effects of FRMD7.
METHODS
Study  protocol:  The  study  protocol  was  approved  by  the
Department of Medicine of the Second Affiliated Hospital,
Zhejiang University (Hangzhou, Zhejiang Province, China).
Written informed consent was also obtained from all mothers
participating in the study. All samples were obtained and used
in a manner compliant with the Code of Ethics of the World
Medical Association (Declaration of Helsinki).
Preparation of human tissue: Human fetal brains at stages 16–
17, 21, and 25 wpc were collected from the Department of
Medicine, Second Affiliated Hospital, Zhejiang University.
Fresh human fetal brain tissues were fixed in 10% formalin
(pH 7.2) for 24 h at room temperature (RT) before analysis.
Immunohistochemistry:  Expression  and  localization  of
FRMD7  was  detected  using  a  MaxVisionTM  Horseradish
Peroxidase-Polymer  Anti-Rabbit  IHC  Kit  (KIT-5004;
Maixin-Bio, Fujian, China) according to the manufacturer’s
protocol.  After  fixing  and  embedding  brain  samples  in
paraffin, 4 µm sections were cut, placed on poly-L-lysine-
coated slides, and dried for 1 h at 60 °C. Brain sections were
then deparaffinized using three changes of xylene separately
for 10, 5, and 3 min intervals, followed by hydration in 100%,
95%, and 75% ethyl alcohol (two changes of 3 min each).
Antigen retrieval was performed by microwaving sections at
98 °C in EDTA buffer (pH 7.4) for 15 min, then cooling the
samples to room temperature (RT). Tissues were incubated in
3% hydrogen peroxide solution for 10 min at RT, then blocked
with goat serum for 10 min. Sections were placed in a damp
box  for  incubation  with  primary  anti-FRMD7  antibodies
(1:200  dilution;  polyclonal  rabbit  anti-human  antibody;
HPA000886; Sigma–Aldrich, St Louis, MO) for 1 h at RT.
Sections were incubated with secondary antibody (goat anti-
rabbit; Maixin-Bio) at for 30 min at RT. After washing with
1×  TBS,  sections  were  incubated  with  DAB  for  5  min.
Negative  controls  were  stained  with  rabbit  normal  serum
instead of primary antibodies. An Olympus microscope was
used for imaging (Olympus BX60; Olympus, Tokyo, Japan).
Reverse transcription-polymerase chain reaction (RT–PCR):
Total RNA (5 µg) was reverse transcribed using oligo dT
using a reverse transcriptase from the NTera-2cell line. For
PCR ampliﬁcation, speciﬁc oligonucleotide primer pairs (10
pmol each) were incubated with 2 µl cDNA template in 25 µl
PCR reaction mixtures containing 2.5 µl 10× PCR buffer,
1.5 mM MgSO4, mixed deoxynucleotides (1 mM each), and
0.5 U KOD PLUS (TOYOBO, Osaka, Japan) polymerase.
The sequences of the primers used are provided Table 1. For
amplification of full-length FRMD7, PCR reactions included:
35 cycles at 94 °C for 2 min; 98 °C for 15 s; 58 °C for 40 s;
68 °C for 2 min 20 s; and a final extension step at 68 °C for 7
min. For the different domains, dilutions of cDNAs were
ampliﬁed for 35 cycles at 94 °C for 2 min, 98 °C for 15 s,
60 °C for 40 s, and 68 °C for 1 min 20 s. Ampliﬁed PCR
products were analyzed by 1% agarose gel electrophoresis,
and β-actin (ACTB) mRNA served as the internal standard.
FRMD7  mutations  included  c.781C>G,  c.886G>C  and  c.
1003C>T [8], which were produced using overlap PCR (Table
1).
Construction of plasmids: Each PCR product was conﬁrmed
by subcloning the ampliﬁed cDNAs into the pGEM-T Easy
Vector System (Promega, Madison, WI) for sequencing. Full-
length  FRMD7  cDNA,  as  well  as  a  1,308  bp  fragment
encoding the ∆FERM domain of FRMD7 (amino acids [aa]
280–714) and a 1,137 bp fragment encoding the ∆FERM+FA
TABLE 1. PRIMERS FOR AMPLIFICATION OF THE DIFFERENT DOMAINS AND MUTATION-TYPE FRMD7.
Name Sense primers (5′-3′) Antisense primers (5′-3′) Product length (bp)
Full-FRMD7 gaagatctatgctacatttaaaagtgc ggggtaccaaagctaaaaagtaattacatggttttag 2145
FERM gaagatctgccaccatgctacatttaaaagtgcag gggtaccaacctgaagaaagcatggtattccac 837
FERM+FA gaagatctgccaccatgctacatttaaaagtgcag gggtaccaactgtcgttcatggtactgagatg 1008
∆FERM ggagatctatgctttcggaagagcccaaat ggggtaccaaagctaaaaagtaattacatggttttag 1308
∆FERM+FA ggagatctatgtgcaggtcctcaccag ggggtaccaaagctaaaaagtaattacatggttttag 1137
781 Upstream gaagatctatgctacatttaaaagtgc catctccgctggccat 795
781 Downstream ggccagcggagatgc ggggtaccaaagctaaaaagtaattacatggttttag 1366
886 Upstream gaagatctatgctacatttaaaagtgc ctggaacgcttgctgc 902
886 Downstream gcagcaagcgttccagt ggggtaccaaagctaaaaagtaattacatggttttag 1258
C1003T gaagatctatgctacatttaaaagtgc gaggtaccattcatggtactgagat 1003
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592(FERM Adjacent domain) domain of FRMD7 (aa 337–714),
were digested with BglII and KpnI, and fused to enhanced
green fluorescent protein (EGFP) in pEGFP-N1 (Invitrogen,
Carlsbad, CA). Mutated versions of FRMD7 (c.781C>G, c.
886G>C and c.1003C>T) were also subcloned into pEGFP-
N1. Alternatively, the 837 bp fragment encoding the FERM
domain of FRMD7 (aa 1–279) and the 1,008 bp fragment
encoding the FERM and FA domains of FRMD7 (aa 1–336)
were subcloned into the BglII and KpnI sites of pEGFP-C1
(Invitrogen) and fused to an NH2-terminal EGFP.
Cell culture and transient transfection: Mouse neuroblastoma
cells  (Neuro-2A)  and  human  embryonic  kidney  293  cells
(HEK293T) were purchased from the Chinese Academy of
Sciences Committee Type Culture Collection Cell Bank/CAS
Shanghai  Institutes  for  Biologic  Sciences  Cell  Resource
Center  (Shanghai,  China).  HEK293T  cells  and  Neuro-2A
cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM;  Invitrogen,  Carlsbad,  CA)  containing  10%  fetal
bovine  serum  (FBS;  Invitrogen),  10%  penicillin,  and
streptomycin. Cultures were maintained in 5% CO2 at 37 °C,
and were passaged every 2–3 days. For immunocytochemical
analyses, cells were grown on chamber slides to 60%–70%
conﬂuence in 24-well plates then transfected with 0.4 µg
plasmid DNA and 1.5 µl Attractene Transfection Reagent
(Qiagen, Valencia, CA) per well. After 6 h, cells were rinsed
and fresh DMEM (containing 10% FBS) was added.
Immunofluorescence  and  F-actin  staining:  Twenty-four
hours after transfection, cells were ﬁxed in 4% formaldehyde
in PBS (50 mM NaPi, 150 mM NaCl, pH 7.5) for 15 min at
RT. After three washes in PBS, cell nuclei were stained with
4',6-diamidino-2-phenylindole  (1:5,000  dilution;  DAPI;
ZhongShan Goldenbridge Biotechnology CO.,LTD, Beijing,
China) for 5 min at RT. F-actin was stained using TRITC-
conjugated rhodamine–phalloidin (77481; Sigma-Aldrich, St.
Louis, MO) fluorescein diluted in PBS and BSA for 45 min
at 37 °C. Morphological features were quantiﬁed using a
confocal laser scanning microscope (Leica TCS SP5 X; Leica,
Wetzlar, Germany).
RESULTS
Expression of FRMD7 in the human fetal brain: Expression
of  the  nystagmus-related  FRMD7  protein  was  examined
during three stages of human fetal development (16–17, 21,
and 25 wpc) and in five different regions (cortex, brainstem,
hippocampus, cerebellum, and diencephalons) for each stage.
At 16–17 wpc, FRMD7 was observed to be highly expressed
in the pons, medulla oblongata, and midbrain (brainstem;
Figure 1A-F), which are important regions associated with
ocular  motor  control.  FRMD7  was  also  observed  in  the
cerebellar region and diencephalons at 16–17 wpc. During the
later stages of fetal development (i.e., 21 and 25 wpc), overall
expression of FRMD7 was found to significantly decrease in
the brainstem, and from the cortex, limited expression was
manifested in the cortex plate (Figure 1G-L).
Subcellular  localization  of  various  forms  of  FRMD7  in
HEK293T  and  Neuro-2a  cells:  To  better  understand  the
function  of  FRMD7,  HEK293T  and  Neuro-2a  cells  were
transiently transfected with various EGFP-tagged fragments
of FRMD7. In these experiments, full-length FRMD7 was
found to be uniformly distributed in the cytoplasm. In contrast,
when various regions of FRMD7 were overexpressed, only
the  COOH-terminal  regions  of  FRMD7  (∆FERM  and
∆FERM+FA)  resulted  in  a  distribution  pattern  that  was
similar to that of full-length FRMD7. However, for these
modified FRMD7 proteins, the expression levels were lower,
and some aggregates were observed in the cytoplasm. For
FRMD7 constructs containing only the NH2-terminal FERM
domain (aa 1–279) of FRMD7, or a combination of the FERM
domain and the FA domain (adjacent to the FERM domain;
aa  294–336),  a  predominantly  nuclear  distribution  was
observed (Figure 2).
Role of F-actin dynamics: It is hypothesized that FRMD7
regulates  neuronal  development  by  influencing  F-actin
dynamics.  Therefore,  EGFP-tagged  mutated  versions  of
FRMD7 were transiently transfected into HEK293T cells and
these cells were stained with TRITC rhodamine–phalloidin to
detect F-actin. In these experiments, both wild-type FRMD7
and c.781C>G and c.886G>C FRMD7 mutants exhibited a
diffuse distribution in the cytoplasm, and also in actin-rich
regions.  However,  another  FRMD7  mutant,  c.1003C>T,
exhibited changes in its subcellular distribution pattern and
did not co-localize with F-actin (Figure 3).
DISCUSSION
FRMD7 is related to the X-linked ICN. FRMD7 mRNA has
recently been shown to have a temporal and spatial expression
pattern  in  the  cerebral  cortex  in  the  developing  human
embryonic  brain  and  early  fetal  brain.  However,  the
expression pattern in other brain regions also related to eyeball
movement and in later development stages of human fetal
brain were not known. In the present study, expression of
FRMD7 was detected during three different stages of human
fetal development and in five specific regions of the brain.
From these experiments, it was observed that expression of
FRMD7 is not restricted to the cortex, since at 16–17 wpc,
FRMD7  is  highly  expressed  in  the  pons,  medulla  and
oblongata. Moreover, moderate expression of FRMD7 was
detected  in  the  cerebellar  region  and  diencephalons.  The
highest levels of expression that were detected correlate with
regions of the brain associated with ocular motor control. In
the cortex, limited expression of FRMD7 in the cortex plate
was also observed, which suggests a role for FRMD7 in the
brainstem.  Furthermore,  in  the  later  stages  of  fetal
development (e.g., 21 and 25 wpc), overall expression of
FRMD7 was significantly lower in the brainstem and cortex.
Therefore, since expression of FRMD7 was not detected in
the cerebellar region and diencephalons in the later stages of
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593development, we hypothesize that FRMD7 mainly affects the
brainstem during early development of the fetal brain.
FRMD7 is a member of the FERM family of proteins,
and for a subset of these proteins, subcellular distribution has
been  shown  to  be  critical  for  their  function  (e.g.,  merlin,
moesin, and FAK) [16,17]. Studies have also shown that the
subcellular localization of most FERM family proteins is not
dependent on the NH2-terminal FERM domain, but rather on
Figure 1. Expression of FRMD7 protein. A-F: FRMD7 protein expression in the brainstem of developing human fetal brain. Sections from
human fetal brainstem tissue were examined by immunohistochemistry with anti-FRMD7 antibody. Positive staining (brown) was showed in
the cytoplasm (arrows), and strong immunoreactivity was detected at 16–17 weeks post-conception (wpc) (A: 100×; D: 400×), while lower
levels of FRMD7 immunoreactivity were observed at 21 wpc (B: 100×, E: 400×) and 25 wpc (C: 100×; F: 400×). Scale bars: (A, B, and C;
400 μm), (D, E, and F; 100 μm). G-L: Immunohistochemical staining of protein FRMD7 in the cortex of human fetal brain tissue using anti-
FRMD7 antibody. Limited expression (arrow) was manifested in the cortex plate at 16–17 weeks post-conception (wpc; G: 100×; J: 400×),
and at 21 wpc (H: 100×, K: 400×) and 25 wpc (I: 100×; L: 400×) there were little positive staining detected. Scale bars: (G, H, and I; 400
μm), (J, K, and L; 100 μm).
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594the  COOH-terminal  domains  of  FRMD7  [17].
Correspondingly, in this study, only constructs containing the
COOH-terminal FERM domain (e.g., ∆FERM and ∆FERM
+FA) produced an expression pattern similar to that of full-
length FRMD7, while proteins lacking the COOH-terminal
domain, yet maintaining the NH2-terminal FERM domain, or
containing the FERM and FA domains, exhibited a primarily
nuclear distribution. In combination, these data suggest that
the COOH-terminus of FRMD7 plays a significant role in
determining the subcellular localization of FRMD7.
When FRMD7 was knocked down in Neuro-2a cells, a
signiﬁcant reduction in the overall length of neurites was
detected,  along  with  an  increase  in  levels  of  F-actin  and
changes in the dynamics between F-actin and G-actin [14].
Based  on  these  results,  a  unique  role  for  FRMD7  in
association with F-actin was identified. However, the role of
FRMD7 mutations in ICN is incompletely understood. Of the
mutation  sites  identified,  most  are  localized  in  the  NH2-
terminal FERM domain of FRMD7. However, it is unclear
how mutations present in different domains eventually lead to
the  same  disease.  We  previously  reported  two  missense
mutations,  c.781C>G  and  c.886G>C,  which  lead  to  an
arginine in the protein 261 loci being substituted for glycine
(p.R261G),  and  glycine  in  the  protein  296  loci  being
substituted for arginine (p.G296R), respectively. A nonsense
mutation (c.1003C>T) was also identified, which results in
the arginine of the protein 335 loci to be substituted for a stop
codon (p.R335X) [8]. Therefore, in this study, rhodamine–
phalloidin staining was used to further characterize the role of
F-actin in relation to these three mutations. In HEK293T cells,
both wild-type and c.781C>G and c.886G>C mutants were
observed  to  co-localize  with  F-actin.  However,  the  c.
1003C>T  mutant  of  FRMD7  (which  produces  a  COOH-
terminal truncated protein), did not co-localize with F-actin.
These findings suggest that FRMD7 may mediate regulation
of the cytoskeleton. Although the c.781C>G and c.886G>C
mutations did not alter the co-localization of FRMD7 and F-
actin, the FERM domain has previously been associated with
Figure 2. Subcellular localization of full-length FRMD7 versus various domains of FRMD7. HEK293T cells transiently transfected with
EGFP-fusion proteins of FRMD7 (green) were stained with DAPI (blue) and imaged. Full-length FRMD7 was diffusely localized to the
cytoplasm, while the NH2-terminal FERM domain (aa 1–279), and the FERM domain plus the FA domain, primarily localized to the nucleus
(arrows). Constructs containing the COOH-terminal region of FRMD7 (e.g., ∆FERM and ∆FERM+FA) exhibited an expression pattern
similar to that of full-length FRMD7, however, the expression level was decreased and some aggregates of these truncated proteins were
detected in the cytoplasm. The results obtained from Neuro-2a cells (not shown) was the same as HEK293T cells. FERM: four-point-one,
ezrin, radixin, moesin; FERM+FA: FERM domain and FERM Adjacent domain; ∆FERM: truncated NH 2-terminal FERM domain; ∆FERM
+FA; truncated NH2-terminal FERM domain and FERM Adjacent domain. Scale bars: 20 μm.
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595regulation of the cytoskeleton. Moreover, the role for FRMD7
in neuronal development is similar to that of other FERM
family proteins, particularly FARP1 and FARP2 [11,18,19],
where their regulation of the cytoskeleton is mediated by the
activation of small GTPases. Therefore, the role of FRMD7
in neuronal development may involve the cytoskeleton.
In summary, the present study demonstrates that FRMD7
is mainly expressed in the brainstem during the early stages
of development of the human fetal brain. The subcellular
localization of FRMD7 is also shown to be dependent on
COOH-terminal regions of FRMD7, as well as the type of
mutation(s) present (e.g., location of the mutant or protein
truncation). For the c.1003C>T mutant of FRMD7, truncation
of  the  COOH-terminus  of  FRMD7  alters  the  relationship
between F-actin and FRMD7. Overall, these ﬁndings indicate
that additional studies are needed to investigate the function
and  mechanism  of  FRMD7  in  neuronal  development,
particularly as it relates to the pathogenesis of ICN.
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Figure 3. Co-localization of F-actin and FRMD7. HEK293T cells transiently transfected with EGFP-tagged wild-type FRMD7 and FRMD7
mutants, c.781C>G and c.886G>C, (shown in green) were stained with TRITC-conjugated rhodamine–phalloidin fluorescein (red). All three
fusion proteins exhibited a diffuse localization pattern in the cytoplasm, and also in actin-rich regions of the HEK293T cells (arrows). However,
HEK293T cells expressing the FRMD7 mutant, c.1003C>T, fused to EGFP, primarily exhibited localization of the fusion protein to the nucleus
and did not co-localize with F-actin (merge). Scale bars: 20 μm.
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